Testing carvedilol and alverine for liver cirrhosis with high blood pressure in the portal vein
Part of Digestive system clinical trials.
This trial is for people with liver cirrhosis who already take carvedilol for portal hypertension (high blood pressure in the liver's main vein). It tests whether adding alverine helps lower that pressure more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with liver cirrhosis (a scarring of the liver).
- You have been taking carvedilol for at least 3 months, at a dose up to 15 mg per day (or the highest dose you can handle).
- You have not taken alverine, papaverine, or similar medicines in the last 4 weeks.
- You have not had a transjugular intrahepatic portosystemic shunt (TIPS) or other procedure that lowers portal pressure, and you have not had a liver transplant.
- You can avoid heavy drinking (more than 1–2 drinks a day) for at least 12 weeks before and during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if alverine, a medicine for gut spasms, can help lower high blood pressure in the liver caused by cirrhosis. You may qualify if you have cirrhosis with high liver pressure and haven't used certain other blood-pressure medicines recently.
This trial tests a medicine called alverine to see if it can lower high blood pressure in the liver's veins (portal hypertension) caused by cirrhosis. It may help prevent complications like bleeding or fluid buildup.
This trial studies alverine to lower portal hypertension, which is high blood pressure in the liver that can happen with cirrhosis. If it works safely, it may reduce pressure-related complications in people with confirmed liver scarring.
This trial tests whether a medicine called carvedilol can lower high blood pressure in the liver veins of people with cirrhosis. It uses a special ultrasound probe to measure the pressure before and after taking the medicine.
This trial tests if the drug carvedilol can prevent liver-related emergencies or death in people with cirrhosis and high blood pressure in the liver. It may help those who are stable right now but at risk for a sudden worsening.
This trial tests whether adding metformin to carvedilol (a standard drug) lowers liver pressure more than carvedilol alone in people with cirrhosis who have had variceal bleeding. The goal is to prevent future bleeding.
Hear when a new Hypertension, Portal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.